Join our daily newsletter At The Bell to receive exclusive market insights
- Invex Therapeutics (IXC) signs an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure
- The company has signed a long-term collaboration and manufacturing agreement with Peptron, for the development of Presedin.
- The agreement will see the treatment manufactured and supplied globally to Invex from Peptron’s manufacturing facility in Korea, which can produce more than 48,000 vials of Presendin per month
- Invex Therapeutics is up 14.7 per cent, trading at 78 cents at 1:13 pm AEST
Invex Therapeutics (IXC) has signed an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure.
The company has signed a long-term collaboration and manufacturing agreement with Peptron, for the development of Presedin. Peptron is a Korean-based biopharma company developing sustained-release peptide-based medicines with high technological barriers to treat chronic diseases.
Under the agreement, Peptron will provide Invex with access to its intellectual property and a defined price per dose for the supply of Presendin – initially for clinical studies, then the first 10 years following the first commercial sale.
Presendin is a treatment for people suffering from idiopathic intracranial hypertension (IIH). IIH results in disabling daily headaches and can compress the optic nerve. The treatment offers a reduced injection frequency and typically leads to greater patient compliance.
Presendin will be manufactured and supplied globally to Invex from Peptron’s manufacturing facility in Korea, which can produce more than 48,000 vials of Presendin per month.
Additionally, Invex has granted Peptron an exclusive license to commercialise it for idiopathic intracranial hypertension (IIH) in Korea.
Chairman of Invex Jason Loveridge said the collaboration was a significant step forward for the company.
“Peptron has years of experience in both the manufacture and clinical development of Exenatide and this collaboration significantly de-risks Invex’s development of Presendin in IIH, by providing access to both drug product as well as to Peptron’s critical and extensive data package and their manufacturing and technical expertise,” Dr Loveridge said.
“As a result, Invex will no longer need to undertake additional animal tolerability and human pharmacokinetic studies for Presendin, which reduces Invex’s development costs and risk and significantly expedites our planned Phase III registration study in IIH.”
Invex Therapeutics was up 14.7 per cent, trading at 78 cents at 1:13 pm AEST.
